International Congress on Abnominal Obesity
Am J Clin Nutr 91: 251S-253S, 2010. First published November 18, 2009; doi:10.3945/ajcn.2009.28449A
 American Journal of Clinical Nutrition, doi:10.3945/ajcn.2009.28449A
Vol. 91, No. 1, 251S-253S, January 2010
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/1/251S    most recent
ajcn.2009.28449Av1
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blackburn, G. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blackburn, G. L
Agricola
Right arrow Articles by Blackburn, G. L
© 2010 American Society for Clinical Nutrition

ORIGINAL RESEARCH COMMUNICATION

From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor {gamma} modulators1,2,3

George L Blackburn

1 From the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

2 Supported by the S Daniel Abraham Chair in Nutrition Medicine and the Harvard Center for Healthy Living, Harvard Medical School, Boston, MA.

3 Address correspondence to GL Blackburn, Beth Israel Deaconess Medical Center, Center for the Study of Nutrition Medicine, Feldberg 880, East Campus, 330 Brookline Avenue, Boston, MA 02155. E-mail: gblackbu{at}bidmc.harvard.edu.

Type 2 diabetes is a complex disease that requires long-term therapy aimed at multiple targets. At Experimental Biology 2009 (www.eb2009.org), held last April in New Orleans, LA, the American Society for Nutrition hosted the symposium "From bench to bedside: novel therapeutic advances through the development of selective peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) modulators." Presenters addressed the latest science on novel pathways that regulate metabolism and insulin resistance, including fibroblast growth factor 21 (FGF21) and adiponectin, as well as advances in our understanding of the biology of PPAR{gamma}, including modes of action and recently discovered side effects of PPAR{gamma} agonists. They also explored the pharmacologic and physiologic actions of FGF21 and adiponectin, metabolic regulators that could provide novel therapeutic opportunities in the future, as well as current data on selective PPAR{gamma} modulators. These molecules offer a new direction in the search for more specific PPAR{gamma} activators that will retain efficacy for the treatment of diabetes without major side effects.




This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
S. A Kliewer and D. J Mangelsdorf
Fibroblast growth factor 21: from pharmacology to physiology
Am. J. Clinical Nutrition, January 1, 2010; 91(1): 254S - 257S.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
F. Ziemke and C. S Mantzoros
Adiponectin in insulin resistance: lessons from translational research
Am. J. Clinical Nutrition, January 1, 2010; 91(1): 258S - 261S.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
L. S. Higgins and A. M DePaoli
Selective peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) modulation as a strategy for safer therapeutic PPAR{gamma} activation
Am. J. Clinical Nutrition, January 1, 2010; 91(1): 267S - 272S.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
W. W. Cheatham
Peroxisome proliferator-activated receptor translational research and clinical experience
Am. J. Clinical Nutrition, January 1, 2010; 91(1): 262S - 266S.
[Abstract] [Full Text] [PDF]